Published August 2015 | Version v1
Journal article

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

Others:
Institut Paoli-Calmettes ; Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)
Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD) ; Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut Gustave Roussy (IGR)
Université Paris-Sud - Paris 11 (UP11)
Oncologie génito-urinaire ; Département de médecine oncologique [Gustave Roussy] ; Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR)
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC) ; Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)
Hôpital Côte de Nacre [CHU Caen] ; CHU Caen ; Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)
Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée)
Clinique Pasteur [Toulouse]
Centre Paul Papin ; CRLCC Paul Papin
Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL) ; UNICANCER
Centre Eugène Marquis (CRLCC)
CRLCC René Gauducheau
Hôpital Foch [Suresnes]
Centre hospitalier Saint-Joseph [Paris] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
CRLC Val d'Aurelle-Paul Lamarque ; CRLCC Val d'Aurelle - Paul Lamarque
Institut Claudius Regaud
Institut Curie [Paris]
Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL) ; UNICANCER
UNICANCER
Hôpital de Toulon/Hyères - Sainte Marguerite [Hyères] (HTH-SM)
Centre Hospitalier Layné ; Centre Hospitalier Layné
Hôpital de la Timone [CHU - APHM] (TIMONE)
Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville)
Hôpital Bretonneau ; Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
Hôpital Dupuytren [CHU Limoges]
Université Catholique de Louvain = Catholic University of Louvain (UCL)
Centre Catherine-de-Sienne [Nantes] (CCS)
Hôpital Saint-André
Clinique Saint-Jean Languedoc [Toulouse] (CSJL)
Institut Jean Godinot [Reims] ; UNICANCER
Clinique Armoricaine de Radiologie [St. Brieuc]
Hopital Saint-Louis [AP-HP] (AP-HP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
CHU Toulouse [Toulouse]
Hôpital Européen Georges Pompidou [APHP] (HEGP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
Université Paris Descartes - Paris 5 (UPD5)

Description

Background: The Glass model developed in 2003 uses prognostic factors for noncastrate metastatic prostate cancer (NCMPC) to define subgroups with good, intermediate, and poor prognosis.Objective: To validate NCMPC risk groups in a more recently diagnosed population and to develop a more sensitive prognostic model.Design, setting, and participants: NCMPC patients were randomized to receive continuous androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-15 phase 3 trial. Potential prognostic factors were recorded: age, performance status, Gleason score, hemoglobin (Hb), prostate-specific antigen, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), metastatic localization, body mass index, and pain.Outcome measurements and statistical analysis: These factors were used to develop a new prognostic model using a recursive partitioning method. Before analysis, the data were split into learning and validation sets. The outcome was overall survival (OS).Results and limitations: For the 385 patients included, those with good (49%), intermediate (29%), and poor (22%) prognosis had median OS of 69.0, 46.5 and 36.6 mo (p=0.001), and 5-yr survival estimates of 60.7%, 39.4%, and 32.1%, respectively (p=0.001). The most discriminatory variables in univariate analysis were ALP, pain intensity, Hb, LDH, and bone metastases. ALP was the strongest prognostic factor in discriminating patients with good or poor prognosis. In the learning set, median OS in patients with normal and abnormal ALP was 69.1 and 33.6 mo, and 5-yr survival estimates were 62.1% and 23.2%, respectively. The hazard ratio for ALP was 3.11 and 3.13 in the learning and validation sets, respectively. The discriminatory ability of ALP (concordance [C] index 0.64, 95% confidence interval [CI] 0.58-0.71) was superior to that of the Glass risk model (C-index 0.59, 95% CI 0.52-0.66). The study limitations include the limited number of patients and low values for the C-index.Conclusion: A new and simple prognostic model was developed for patients with NCMPC, underlying the role of normal or abnormal ALP.

Abstract

International audience

Additional details

Created:
December 4, 2022
Modified:
December 1, 2023